Related Experiment Video
Updated: Aug 18, 2026
Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012
Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant,
A Riezebos-Brilman1, J Regts, E-J Freyschmidt
1Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen (UMCG), Ant. Deusinglaan 1, 9713 AV Groningen, The Netherlands.
Abstract:
Despite promising preclinical results of various therapeutic anticancer immunization strategies, these approaches may not be effective enough to eradicate tumors in cancer patients. While most animal models are based on fast-growing transplantable tumors, malignancies in, for example, cervical cancer patients in general develop much more slowly, which may lead to immune suppression and/or immune tolerance. As a consequence, the immunomodulating signal of any therapeutic immunization regimen should be sufficiently potent to overcome this immunocompromised condition. In previous studies, we demonstrated that an experimental vaccine against human papillomavirus (HPV)-induced cervical cancer, based on Semliki Forest virus (SFV), induces robust HPV-specific cellular immune responses in mice. Now we studied whether this strategy is potent enough to also prime a cellular immune response in immune-tolerant HPV transgenic mice, in which CTL activity cannot be induced using protein or DNA vaccines. We demonstrate that, depending on the route of immunization, SFV-expressing HPV16 E6 and E7 indeed has the capacity to induce HPV16 E7-specific cytotoxic T cells in HPV-transgenic mice.
Insights
This study shows that a novel Semliki Forest virus (SFV) vaccine can overcome immune tolerance in mice, effectively generating cytotoxic T cells against human papillomavirus (HPV) in models of cervical cancer.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- Therapeutic anticancer immunization strategies show promise but often fail in patients due to slow-growing tumors causing immune suppression or tolerance.
- Existing animal models may not accurately reflect the challenges of slow-developing human malignancies.
- Potent immunomodulation is required to overcome immunocompromised conditions in cancer patients.
Purpose of the Study:
- To evaluate the potency of a Semliki Forest virus (SFV)-based therapeutic vaccine in overcoming immune tolerance.
- To determine if the SFV-based vaccine can induce a cellular immune response in immune-tolerant human papillomavirus (HPV) transgenic mice.
- To assess the capacity of the vaccine to prime cytotoxic T lymphocyte (CTL) activity against HPV antigens.
Main Methods:
- Utilized SFV-expressing HPV16 E6 and E7 antigens for vaccination in HPV transgenic mouse models.
- Administered the experimental vaccine via different routes of immunization.
- Assessed the induction of HPV16 E7-specific CTL responses in vaccinated mice.
Main Results:
- The SFV-based vaccine demonstrated the capacity to induce HPV16 E7-specific CTLs in HPV-transgenic mice.
- The route of immunization influenced the vaccine's ability to prime cellular immune responses.
- This strategy proved effective in immune-tolerant mice where protein or DNA vaccines failed to induce CTL activity.
Conclusions:
- The SFV-based HPV vaccine strategy is potent enough to overcome immune tolerance and prime HPV-specific cellular immunity.
- This approach holds potential for therapeutic vaccination against HPV-induced cancers, including cervical cancer.
- Further research into optimal immunization routes may enhance vaccine efficacy in clinical settings.
